Small Interfering RNA Drug Class List

Drugs in Drug Class: Small Interfering RNA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Genzyme Corp	QFITLIA	fitusiran sodium	SOLUTION;SUBCUTANEOUS	219019-001	Mar 28, 2025		RX	Yes	Yes	9,376,680		Y	Y
Genzyme Corp	QFITLIA	fitusiran sodium	SOLUTION;SUBCUTANEOUS	219019-002	Mar 28, 2025		RX	Yes	Yes
Genzyme Corp	QFITLIA	fitusiran sodium	SOLUTION;SUBCUTANEOUS	219019-001	Mar 28, 2025		RX	Yes	Yes	9,127,274		Y	Y
Genzyme Corp	QFITLIA	fitusiran sodium	SOLUTION;SUBCUTANEOUS	219019-001	Mar 28, 2025		RX	Yes	Yes
Genzyme Corp	QFITLIA	fitusiran sodium	SOLUTION;SUBCUTANEOUS	219019-001	Mar 28, 2025		RX	Yes	Yes
Genzyme Corp	QFITLIA	fitusiran sodium	SOLUTION;SUBCUTANEOUS	219019-002	Mar 28, 2025		RX	Yes	Yes	11,091,759

Market Dynamics and Patent Landscape for Small Interfering RNA (siRNA) Drugs

Last updated: January 17, 2026

Executive Summary

Small Interfering RNA (siRNA) therapeutics represent a transformative class in gene silencing, with promising applications across genetic, viral, and oncological diseases. The global siRNA market is projected to reach approximately USD 1.4 billion by 2027, with a compound annual growth rate (CAGR) of over 20%, driven by technological advancements, strong clinical pipelines, and strategic partnerships. The patent landscape is highly active, characterized by extensive Patent Cooperation Treaty (PCT) filings, key patents held by biotech giants like Alnylam Pharmaceuticals and Moderna, and broad claims covering delivery technologies and specific sequences. Navigating this landscape is essential for innovators seeking market entry or licensing opportunities.

---

What Are the Market Drivers Shaping siRNA Therapeutics?

Factor	Description	Impact
Technological Innovation	Advances in delivery mechanisms (lipid nanoparticles, GalNAc conjugates) enhance bioavailability and specificity.	Catalyzes clinical success and commercial adoption.
Regulatory Approvals	First approvals (e.g., Onpattro in 2018) validate safety and efficacy.	Creates regulatory precedents and boosts investor confidence.
Unmet Medical Need	Diseases like transthyretin amyloidosis and hypercholesterolemia lack effective treatments.	Drives R&D focus and market entry.
Strategic Partnerships	Collaborations between pharma and biotech enhance pipeline robustness.	Accelerates commercialization.
Market Penetration and Reimbursement	Growing reimbursement pathways facilitate broad access.	Supports sustained growth.

---

Current Market Landscape

Global Market Size and Growth Projections

Year	Market Value (USD Billion)	Growth Rate (CAGR)	Notes
2022	0.6	—	Baseline for models
2023	0.75	20%	Increased approvals and partnerships
2027	1.4	20.5%	Projected market size

Sources: GlobalData, 2023; MarketsandMarkets, 2022

Key Indications and Pipeline Products

Indication	Lead Drugs	Status	Clinical Phase	Notes
Hereditary transthyretin amyloidosis	Patisiran (Onpattro), Vutrisiran	Approved	N/A	First FDA-approved siRNA drug (2018)
Hypercholesterolemia	Inclisiran (Leqvio)	Approved	N/A	Approved in U.S. and EU (2020s)
COVID-19 (Emerging)	siRNA candidates	Early	Preclinical	Potential antiviral applications
Oncology & Rare Diseases	Multiple candidates	Numerous	Phase 1-3	Growing pipeline focus

Major Industry Players and Collaborators

Company	Specialty/Focus	Key Patents/Technologies	Collaborations	Market Share
Alnylam Pharmaceuticals	Pioneered siRNA	Lipid nanoparticle or GalNAc delivery patents	Regeneron, Novartis	~40% (approximate)
Moderna	Delivery systems, novel therapeutics	Multiple pending patents	AstraZeneca, Vertex	Growing influence
Silence Therapeutics	Novel siRNA modifications	Patent filings in chemistry	Multiple licensing deals	Niche segment
Arrowhead Pharmaceuticals	Hyper-targeted delivery	Proprietary conjugation tech	Collaborations with Janssen	Emerging player

---

Patent Landscape Analysis

Patent Filing Trends (2010–2023)

Year	Number of Patent Filings	Major Patent Holders	Focus Areas
2010–2015	150	Alnylam, Tekmira (Thermo Fisher), Santaris (Roche)	Delivery methods, sequence specificity
2016–2020	350	Moderna, Arcturus, Alnylam	Modified nucleotides, conjugation technologies
2021–2023	250+	Multiple, including startups	Next-gen delivery, broad composition patents

Note: Patent filings predominantly published via PCT applications and EPO databases.

Key Patent Portfolios and Their Focus

Patent Portfolio	Holder	Technological Focus	Scope
Lipid nanoparticle delivery	Tekmira, Acuitas	Lipid composition, encapsulation techniques	Composition and process patents
GalNAc conjugates	Alnylam, Silence Therapeutics	Sugar-mediated hepatocyte targeting	Sequence-specific and conjugation patents
Chemical modifications	Moderna, Arcturus	Modified nucleotides for stability	Structure-function patents
Manufacturing methods	Multiple	Scale-up processes	Bioprocessing patents

---

Regulatory Environment and Policy Impact

Agency	Decisions & Guidelines	Relevance
FDA	First siRNA approval (2018), fast-track options	Accelerates development timelines
EMA	Conditional approvals, adaptive pathways	Permits access during emergencies
OECD	Patent and data exclusivity policies	Protects innovation investments
U.S. Patent Office	Examination of biotech patents	Shapes scope of patentability

Intellectual Property Strategies

• Broad Claims and Composition Patents: Protect sequences, delivery vehicles, and modifications.
• Method Patents: Cover manufacturing and administration protocols.
• Combination Patents: Cover siRNA with other therapeutics.
• Freedom to Operate (FTO) Analyses: Critical before entering markets, given overlapping patent claims.

---

Comparative Analysis of Delivery Technologies

Technology Type	Key Patents	Advantages	Limitations	Examples
Lipid Nanoparticles (LNPs)	Tekmira, Acuitas	Well-characterized, scalable	Potential immunogenicity	Onpattro, COVID-19 vaccines
GalNAc Conjugates	Alnylam	Liver targeting, low toxicity	Limited to hepatic diseases	Inclisiran, Givlaari
Polymer-based Systems	Polymerscience, Moderna	Enhanced stability	Complex manufacturing	Experimental
Aptamer-based Delivery	Multiple startups	High specificity	Development complexity	Early-stage

---

Questions in the Market and Patent Space

What Are the Main Opportunities for Innovation?

• Development of tissue-specific delivery beyond liver targeting.
• Enhancement of stability and half-life for systemic circulation.
• Cost-effective manufacturing processes.
• Novel chemical modifications to minimize immunogenicity.
• Expansion into non-hepatic indications.

What Are the Patent Challenges and Risks?

• Overlapping claims leading to potential infringement.
• Patent thickets complicating freedom to operate.
• Expiry of foundational patents (e.g., some lipid nanoparticle patents by Tekmira expire around 2030).
• Variability in patent statutes across jurisdictions affecting global strategies.
• Emergence of patent disputes, requiring legal navigation.

How Do Patent Strategies Differ Across Market Leaders?

Aspect	Alnylam	Moderna	Silence Therapeutics
Focus	Sequence patents, GalNAc conjugates	Delivery platforms, novel chemistry	Chemistry modifications, chemical synthesis
Approach	Broad composition claims	Narrow, specific method claims	Combination of both strategies
Expansion	Licensing and cross-licensing	In-house innovation + licensing	Niche focus with strategic partnerships

---

Comparison with Other Gene-Editing Modalities

Aspect	siRNA Drugs	CRISPR-based Therapies	Antisense Oligonucleotides
Mechanism	Post-transcriptional gene silencing	Gene editing	Gene modulation or silencing
Market Maturity	Commercialized, approved drugs	Clinical trials, emerging	Several approved (e.g., Spinraza)
Patent Complexity	Extensive delivery and sequence patents	Focused on editing tools, delivery	Similar, with focus on chemistry
Key Challenges	Delivery, off-target effects	Off-target editing, delivery	Similar to siRNA, but with different delivery systems

---

Key Takeaways

• The siRNA market is undergoing rapid growth driven by technological advances, improved delivery platforms, and regulatory endorsements.
• Regulatory approvals, notably Alnylam’s Onpattro (2018) and Novartis’ Leqvio (2020), underpin the commercial viability of siRNA therapeutics.
• The patent landscape is highly active, with dominant players holding extensive portfolios covering delivery, modifications, and sequences—raising both opportunities and licensing considerations.
• Strategic patent filings focus on improving stability, targeting specificity, and manufacturing processes, which are crucial for sustaining competitive advantage.
• Market entry requires thorough FTO analysis, with potential risks of patent infringement, especially in overlapping claims.
• Future innovation opportunities center on expanded tissue targeting, new indications, and manufacturing efficiency, amid ongoing patent thickets and legal complexities.

---

FAQs

Q1: How do patent expirations impact the siRNA market?
Patent expirations, notably of core lipid nanoparticle patents, open avenues for generic or biosimilar development, potentially reducing costs and increasing access. However, new patents on improved delivery systems can extend exclusivity.

Q2: Which jurisdictions are most active in siRNA patent filings?
The United States (USPTO), Europe (EPO), and China dominate patent filings, reflecting strategic focus for market expansion and protection.

Q3: What are the primary delivery technologies covered by patents?
Lipids (LNPs), GalNAc conjugates, polymers, and aptamers are primary delivery methods with extensive patent coverage.

Q4: How do regulatory policies influence patent strategies?
Regulatory pathways facilitate accelerated approval, encouraging patent strategies that balance broad claims with compliance to evolving guidelines.

Q5: What role do licensing and collaborations play in siRNA innovation?
Partnerships enable access to proprietary technologies, accelerate pipeline development, and mitigate patent infringement risks.

---

References

1. MarketsandMarkets. "siRNA Therapeutics Market." 2022.
2. GlobalData. "Gene Silencing Technologies." 2023.
3. Alnylam Pharmaceuticals. "Annual Report 2022."
4. U.S. Patent and Trademark Office. Public Patent Data, 2010–2023.
5. EMA and FDA approval records for siRNA drugs.